61. 自己免疫性溶血性貧血 Autoimmune hemolytic anemia Clinical trials / Disease details
臨床試験数 : 137 / 薬物数 : 127 - (DrugBank : 55) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003924-19-BG (EUCTR) | 29/12/2020 | 23/09/2020 | Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA | Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: RVT-1401 Product Code: RVT-1401 INN or Proposed INN: RVT-1401 Other descriptive name: RVT-1401 | Immunovant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | United States;Hungary;Poland;Spain;Thailand;Israel;Bulgaria;United Kingdom;Korea, Republic of | ||
| 2 | EUCTR2019-003924-19-PL (EUCTR) | 04/11/2020 | 25/08/2020 | Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA | Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: RVT-1401 Product Code: RVT-1401 INN or Proposed INN: RVT-1401 Other descriptive name: RVT-1401 | Immunovant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | Bulgaria;Israel;United Kingdom;Korea, Republic of;United States;Hungary;Thailand;Spain;Poland | ||
| 3 | EUCTR2019-003924-19-HU (EUCTR) | 07/10/2020 | 17/08/2020 | Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA | Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: RVT-1401 Product Code: RVT-1401 INN or Proposed INN: RVT-1401 Other descriptive name: RVT-1401 | Immunovant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | United States;Hungary;Poland;Thailand;Spain;Bulgaria;Israel;United Kingdom;Korea, Republic of | ||
| 4 | NCT04253236 (ClinicalTrials.gov) | August 11, 2020 | 21/1/2020 | To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). | A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia | Drug: RVT-1401 680 mg/weekly;Drug: RVT-1401 340 mg/weekly | Immunovant Sciences GmbH | NULL | Terminated | 18 Years | N/A | All | 5 | Phase 2 | United States;Israel;Korea, Republic of;Spain;Thailand;United Kingdom |
| 5 | EUCTR2019-003924-19-ES (EUCTR) | 25/05/2020 | 14/01/2020 | Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA | Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: RVT-1401 Product Code: RVT-1401 INN or Proposed INN: RVT-1401 Other descriptive name: RVT-1401 | Immunovant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | United States;Hungary;Poland;Thailand;Spain;Romania;Bulgaria;Israel;United Kingdom;Korea, Republic of | ||
| 6 | EUCTR2019-003924-19-GB (EUCTR) | 26/02/2020 | 13/03/2020 | Non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia - ASCEND-WAIHA | Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: RVT-1401 Product Code: RVT-1401 INN or Proposed INN: RVT-1401 Other descriptive name: RVT-1401 | Immunovant Sciences GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 2 | United States;Thailand;Spain;Romania;Israel;United Kingdom;Korea, Republic of |